Table 2.
Adverse events for each agent
| Type of agents | Agents | Adverse events |
|---|---|---|
| γ-Secretase inhibitors (GSIs) | MK-0752 | Gastrointestinal toxicity (mainly diarrhea) |
| PF-03084014 | Nausea and vomiting | |
| BMS-906024 | Tolerable gastrointestinal toxicity | |
| MRK-560 | Did not show obvious gastrointestinal pathological changes and thymus T cell development defects | |
| ADAM inhibitors | G1254023X | No records of adverse events related to the drug found in the literature |
| Monoclonal antibody targeting NOTCH1 | OMP-52M51 | May be resistant to T-ALL of carried two activation mutations of NOTCH1 gene: p.Q1584H and p.L1585P |
| mAb604.107 | No records of adverse events related to the drug found in the literature | |
| Direct inhibition of NOTCH1 transcription factor complex | SAHM1 | No records of adverse events related to the drug found in the literature |
| SERCA inhibitors | Thapsigargicin | Severe dose-limited cardiotoxicit |
| JQ-FT | Complex process and poor practicality | |
| Clerodane diterpene casearin J (CJ) | No records of adverse events related to the drug found in the literature | |
| CAD204520 | No weight loss, no adverse effects on behavior, and no signs of acute cardiotoxicity or gastrointestinal metaplasia |